BioSpace News Archive

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported fourth quarter and full year 2019 financial results.

Biogen Inc. announced that the Biogen Foundation has committed $10 million to support global response efforts and communities around the world impacted by the COVID-19 pandemic.

Benchmark Electronics, Inc. announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on April 14, 2020 to shareholders of record at the close of business on March 31, 2020..

- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis - Company Reaffirms it is on Schedule to Complete PRV-031 (teplizumab) Rolling BLA Submission for Prevention or Delay of T1D in At-risk Individuals

Clinical trial results in Acute Respiratory Distress Syndrome supported Fast Track designation by FDA and designation by the Biomedical Advanced Research and Development Authority as a “Highly Relevant” program for COVID-19 and other pathogens

TransEnterix, Inc. announced its operating and financial results for the fourth quarter and full-year 2019.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced financial results for the fourth quarter and full year ended December 31, 2019. Recent Highlights Nano-Pulse Stimulation™ (NPS™) technology was highlighted in three clinical study presentations demonstrating its high clearance rates of benign skin lesions at the Annual Meeting of the American Society for Dermatol

-Firdapse ® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million -GAAP Net Income of $32 Million for Fiscal Year 2019 -Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020 -Firdapse Supply Chain in Solid Position-Significant Safety Stock -Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPR

A quantitative survey conducted by Continuum Clinical indicates as many as one third of clinical research study sites were anticipating significant COVID-19-related interruptions to clinical trial recruitment and retention rates in the weeks and months ahead, even before the federal government declared a National Emergency, and states moved to limit the activities of certain groups.

Celltex Therapeutics Corporation (“Celltex”), a Houston, Texas-based biotechnology company founded in 2011 and focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (“MSCs”), today announced that it has begun active discussions with the FDA regarding a study using MSCs against Coronavirus (“COVID-19”)-type symptoms. Celltex has researched safety and efficacy from the use o